CN045

CN045 is a brain-penetrable, central nervous system (CNS)-active small molecule being developed by Cashel Neural (a spin-off of the Cleveland Clinic) for the treatment of multiple sclerosis (MS). Discovered via a phenotypic screen of approximately 20,000 CNS-biased compounds, CN045 promotes the differentiation of oligodendrocyte progenitor cells (OPCs) into mature, myelin-producing oligodendrocytes, thereby facilitating remyelination. Preclinical studies have demonstrated that CN045 significantly increases remyelination in both white and gray matter regions of the brain in cuprizone/rapamycin-induced demyelination mouse models, and enhances myelin-like ensheathment in human iPSC-derived and adult OPCs. Target-identification and cheminformatic analyses implicate the muscarinic acetylcholine receptor M1 (CHRM1) and the histamine H3 receptor (HRH3) as its primary biological targets.

Other names

CN-045CN045CN 045Cashel Neural compound 045